AADI — Aadi Bioscience Income Statement
0.000.00%
Last trade - 00:00
- $48.98m
- -$29.58m
- $24.35m
- 25
- 47
- 39
- 30
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 15 | 1.12 | 15.2 | 24.4 |
Cost of Revenue | |||||
Gross Profit | — | — | — | 13.9 | 21.5 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 24.4 | 21.4 | 112 | 77.9 | 96.3 |
Operating Profit | -24.4 | -6.36 | -111 | -62.7 | -71.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -23.3 | -4.32 | -110 | -60.5 | -65.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | -23.3 | -4.32 | -110 | -60.5 | -65.8 |
Net Income Before Extraordinary Items | |||||
Net Income | -23.3 | -4.32 | -110 | -60.5 | -65.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -23.3 | -4.32 | -110 | -60.5 | -65.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -7.91 | -1.52 | -6.95 | -2.52 | -2.44 |